Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Core Insights - Regeneron Pharmaceuticals, Inc. reported Q3 earnings with revenues of $3.75 billion and earnings per share of $11.83 on a normalized basis, and $13.62 on a non-normalized basis, leading to a surge in its stock price [1] Company Summary - Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, and operates within the pharmaceutical industry [1] - The company is involved in providing detailed financial forecasts, product sales, and market analysis for major pharmaceutical companies [1] Industry Context - The article emphasizes the importance of keeping up with stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that drive valuations [1]